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ABSTRACT 
 
Antimicrobial peptides are active against bacteria, fungi and viruses as part of the 
innate immune system in animals and insects.  Such peptides are currently produced by 
extracting them from the host organism or by solid phase peptide synthesis; both 
techniques are expensive and produce low yields.  Recombinant DNA technology opens 
a window to produce these peptides inexpensively and in large quantities utilizing E. coli 
expression systems.  Two antimicrobial peptides, indolicidin and PGQ, were the focus of 
this work.  They are short amphipathic alpha helical antimicrobial peptides that target a 
broad range of microorganisms.  Genes encoding multimers of indolicidin, PGQ and a 
hybrid of indolicidin:PGQ were placed into protein expression vectors pET32a+ and 
pET43.1a+, for peptide production in E. coli.  A combination of multimerization and the 
use of a fusion protein were utilized to mask the toxicity of these peptides in E. coli.  The 
multimerized peptide fusion construct was purified using Ni/NTA affinity 
chromatography.  Methionine residues flanking each monomeric unit were utilized to 
enable cleavage of the multimerized protein and liberating a biologically active peptide.  
A Trx:indolicidin trimer fusion was produced in the greatest yield of all constructs 
investigated.  Upon cyanogen bromide cleavage, a band corresponding to the theoretical 
molecular weight of an indolicidin monomer was observed with SDS-PAGE.  
Antimicrobial activity of monomeric recombinant indolicidin was tested resulting in 
zones of clearing.  Overall the results indicate that multimerizing antimicrobial peptide 
genes can potentially produce a larger quantity of peptide per bacterial cell.  These 
studies suggest that multimerization of antimicrobial peptide genes represents a means to 
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control in vivo toxicity of the recombinant peptides and increase production relative to 
single gene fusions.  
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BACKGROUND 
 
Antimicrobial Peptides 
History of Antimicrobial Peptides 
 Small peptides that fight microbial infection are natural antibiotics that function 
as part of the innate immune system of vertebrates and invertebrates (Sitaram and 
Nagaraj, 1999).  This system, present since birth, attempts to continually keep microbial 
infection under control.  Antimicrobial peptides have been classified based on their 
tertiary structures into categories such as linear peptides, alpha helical peptides, beta 
sheet peptides, and single amino acid rich sequence peptides (Figure 1) (Epand and 
Vogel, 1999).  The action of these peptides ranges from physical barriers to cell mediated 
immune responses to microrganisms (Nicolas and Mor, 1995).  Thus far over 100 
different antimicrobial peptides have been discovered in vertebrates.  These discoveries 
may help medicine, as many organisms have become resistant to antibiotics currently in 
use.  Many of these peptides are structurally similar to each other and typically range in 
molecular weight from 1,000-5,000 Da, are polycationic, and span the bacterial 
membrane. 
 
Classification 
 There are five main groups of antimicrobial peptides, delineated by structural 
characteristics (Figure 1).  The amphipathic helical peptides were first identified in 
amphibians and are secreted through the skin.  Most consist of linear peptides ranging 
from 20-36 residues long, which are cationic and have varying numbers of lysine 
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residues.  Their activity is stimulated by cationic binding to membranes as a result of α-
helical formation in an anisotropic environment (Spencer, 1992).  There are also α-helical 
peptides, which are hydrophobic and slightly anionic (Epand and Vogel, 1999).   
 
Figure 1 Classification of Antimicrobial Peptides  
The classification of antimicrobial peptides, which is determined based on structure of 
each peptide group. Indolicidin and PGQ are highlighted because these are the peptides 
used for this project. 
 
 
Trisulfide-rich peptides, such as defensins and β-defensins, range from 29-42 
amino acid residues long (Lehrer et al,1993) and belong to the class of β-sheet and cyclic 
peptides.  These Arg-rich peptides play an important role in the nonoxidative 
microbicidal mechanism in which cells produce intracellular phagocytotic vacuoles, 
which ingest microorganisms (Selsted et al, 1993).  Both defensins and β-defensins 
exhibit a broad range of activity against gram-positive and gram-negative bacteria, 
mycobacteria, spirochetes, fungi and enveloped viruses.   The main distinguishing factor 
of the defensin family is a triple stranded anti-parallel β-sheet interconnected with 
disulfide bonds (Nicolas and Mor, 1995). 
Classification of Antimicrobial Peptides
Amphipathic and 
hydrophobic 
helices
Magainin
PGQ
Cyclic peptides and  ß-
sheet structures
Tachyplesisns, 
protegrins, defensins
Peptides with irregular 
amino acid composition
Cathelicidins
Indolicidin,
tritrpticin, PR-
39, prophenin
Peptides with thio-
ester rings
Lantibiotics
Nisin, 
cinnamycin
Peptaibols
Trichogin, 
alamethicin
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 Some antimicrobial peptides are characterized by an unusually high abundance of 
one or two amino acids.  Indolicidin and tritrpticin contain large numbers of tryptophan 
residues; tryptophan is generally not an abundant amino acid in peptides or proteins 
(Epand and Vogel, 1999).  The proline and arginine-rich antimicrobial peptides are 
composed of more than 60% pro and arg collectively.  They have highly repetitive 
sequences (eg. Arg-Pro-Pro or Pro-Arg-Pro), and are mainly active against gram-negative 
bacteria (Agerberth et al, 1991).   
Peptides with thio-ester rings, also referred to as lantibiotics, are produced by 
bacteria and contain small ring structures enclosed by a thio-ester bond (Epand and 
Vogel, 1999).  Finally, peptailbols contain a high number of α-amino-isobutyric acid 
residues.  This enables the peptides to form a α-helical structure in a particular 
conformation.  These peptides are also acylated at the N-terminus, which favors their 
insertion into membranes (Epand and Vogel, 1999).    
The antimicrobial peptides indolicidin and PGQ (highlighted in red in Figure 1) 
are the main focus of this thesis.  They were chosen due to their activity against microbes 
cultured from a sample of solid waste for which the expression of these peptides is 
targeted.  A library of antimicrobial peptides was tested for activity against this solid 
waste sample, and indolicidin and PGQ demonstrated the best antimicrobial activity 
(Mello, unpublsihed). 
 
Indolicidin   
 Indolicidin was first discovered in the cytoplasmic granules of bovine neutrophils 
(Falla et al, 1996).  It belongs to the cathelicidin family of proteins, which are 
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distinguished by variable C-termini and common amino acid structure (Sitaram and 
Nagaraj, 1999).   
 The smallest of all naturally occurring linear antimicrobial peptides, indolicidin is 
only 13 amino acids long.  Its unique shape, not belonging to either the alpha helix or 
beta sheet family, is a result of its primary structure, consisting of 39% tryptophan and  
MIC = minimum inhibitory concentration  
Table 1 Antimicrobial Activity of Indolicidin 
 
 
23% proline (Falla et al, 1996).  It also contains only 6 different amino acids and is 
amidated at the carboxyl terminus in nature.  Indolicidin is active against gram-negative 
and gram-positive bacteria as well as fungi and protozoa.  Natural indolicidin is active in 
small (µg/ml) quantities against the organisms listed in Table 1.  It also exhibits antiviral 
(Subbalakshmi et al, 1996)
(Selsted et al, 1992)
(Falla et al, 1997)
(Staubitz et al, 2001)
(Falla et al, 1996)
4
10
8
12
8
S. aureus 
ATCC 8530
502A
ATCC 25923
Newman
RN4220
(Falla et al, 1997)4S. epidermidis C621
(Falla et al, 1997)
(Falla et al, 1997)
64
8
S. typhimurium
14028s
MS7953s
(Falla et al, 1997)
(Falla et al, 1997)
(Falla et al, 1997)
64
64
4
P. aeruginosa
H103
K799
Z61
(Subbalakshmi et al, 1996)25C. utilis CBS 4511
(Subbalakshmi et al, 1996)25S. cerevisiae PEP 43
(Subbalakshmi et al, 1996)
(Selsted et al, 1992)
(Falla et al, 1997)
(Falla et al, 1997)
(Staubitz et al, 2001)
25
10
16
4
28
E. coli
W 160 37
ML35
UB1005
DC2
DH5α
ReferenceMIC (µg/ml)Microorganism
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activity against HIV-1  (Sitaram and Nagaraj, 1999).  Unfortunately, it is cytotoxic to rat 
and human T lymphocytes, and lyses red blood cells (Falla et al, 1996), but may have 
practical applications in textiles for biological agent decontamination.   Indolicidin has 
been shown to inhibit DNA synthesis through penetration into the cytoplasmic membrane 
(Subbalakshmi and Sitaram, 1998).  Lysis of the bacteria does not occur, but rather 
filamentation of the cells and blockage of replication occurs due to the blockage of 
thymidine incorporation.   
 
PGQ    
 PGQ stands for peptide with an amino-terminal glycine and carboxyl-terminal 
glutamine and comes from the African clawed frog Xenopus laevis (Moore et al, 1991).  
It is in the group of antimicrobial peptides called magainins, a sub-class of amphipathic 
α-helical peptides, which are secreted from the skin of Xenopus laevis.  All peptides in 
the magainin family range from 21-26 amino acids long and are lysine rich basic proteins 
(Moore et al, 1991).  They are released from the frog upon injury or adrenergic 
stimulation to battle against gram-negative and gram-positive bacteria, fungi and 
protozoa.  These and other peptides are stored in the skin in large granules.  The stomach 
of Xenopus laevis also contains many antimicrobial peptides, including PGQ.  Within the 
stomach, PGQ is stored in the granular multinucleated cells in the gastric mucosa.    
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Mechanism of Action 
 Many mechanisms of action have been proposed for antimicrobial peptides.  One 
mechanism of α-helical and β-sheet peptides is targeted towards the lipid bilayer of the 
bacteria by use of self-promoted uptake where the peptide embeds itself within the lipid 
bilayer forming a channel (Falla et al, 1996).   This increases the rate of leakage of the 
cytoplasmic membrane of gram-negative and gram-positive cells (Figures 2 and 3) 
through cationic binding to the negatively charged lipid membrane (Figure 4) (Epand and 
Vogel, 1999).  This binding is achieved during tertiary folding of the peptides upon 
association with the bacterial cell membrane (Hancock and Rozek, 2002).    For many 
peptides, excluding indolicidin, this inhibits their toxicity to eukaryotic neutrally  
 
Figure 2 Gram-Negative Bacterial Cell Wall 
This represents the composition of a gram-negative bacteria cell wall including the cell 
membrane.  This differentiates from the gram-positive cell membrane, because it contains 
a cell wall (shown in green). 
http://www.bact.wisc.edu/microtextbook/bacterialstructure/CellWall.html 
 
 
Cell Wall 
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Figure 3 Gram-Positive Bacterial Cell Membrane  
This represents the gram-positive cell membrane, which includes the peptidoglycan layer.  
This differs from the gram-negative cell because it lacks the cell wall. 
http://www.bact.wisc.edu/microtextbook/bacterialstructure/CellWall.html 
 
 
charged cell membranes (Huang et al, 2000).   Indolicidin has the ability to break through 
the lipid bilayer by cationic binding, but exerts its activity by inhibition of DNA synthesis 
(Subbalakshmi and Sitaram, 1998).   Direct interaction with the lipid bilayer was 
hypothesized after replacing L-amino acids with all D enantiomers.  This did not inhibit 
membrane binding due to stereospecific protein receptors as previously thought (Huang 
et al, 2000).  Several peptides can influence molecular synthesis at concentrations that do 
not cause the breakdown of the membrane potential, suggesting that other mechanisms 
are important in addition to effects on membrane permeability.  Activity of the proline-
arginine rich peptide PR-39 leads to inhibition of protein synthesis and induction of 
degradation of proteins required for DNA replication (Ramanthan et al, 2002).  Other 
peptides have clearly been shown to permeabilize the membrane and cause cytoplasmic 
leakage (Hancock and Rozek, 2002).  Several cathelicidins have been shown to decrease 
 15 
 
bacterial respiration, caused by deterioration of the inner membrane (Ramanathan et al, 
2002).   
 
Figure 4 Proposed Membrane Permeability Mechanism for α-helical Peptides  
This mechanism of action of antimicrobial peptides involves the permeation of the lipid 
bilayer.  This is achieved when the cationic peptide interacts with the anionic phosolipid 
bilayer.  The peptide then forms a pore with multiple peptides and thus enters the cell 
(Epand and Vogel, 1999). 
 
Potential Applications 
 Antimicrobial peptides are now being investigated by many pharmaceutical 
companies for their wide range of activity against many bacteria and fungi. Due to an 
increase in bacterial resistance to many antibiotics, antimicrobial peptides are a promising 
approach in the development of new drugs (Hancock and Rozek, 2002).  A potentially 
important feature is their low probability of selecting for resistance in target microbes 
because they have evolved as part of innate immune responses.  Antimicrobial peptides 
bind and kill bacteria, fungi and viruses; this may be useful in biological decontamination 
and preservation of food products.  A major challenge is production of these small 
peptides in commercial quantities.  For production of these peptides to be valuable in 
industry, they must be produced in an environmentally safe and cost effective manor.    
 16 
 
 
Current Methods of Production 
 As mentioned above, these peptides were discovered in invertebrates and 
vertebrates as part of the innate immune system.  For years they have been extracted from 
eukaryotic tissue to test their mechanism of action and classify the peptides.  This 
requires tissue extraction or eukaryotic cell expression, which produces low yields of 
protein.  Solid phase peptide synthesis is currently used to produce natural peptide 
sequences, as well as variations, to create novel antimicrobial peptides.  This procedure 
requires hazardous chemicals and costly reagents.  In contrast, recombinant DNA 
technology has been used to clone natural or synthetic genes in bacteria, fungi, plants, or 
yeast cells for increased production of many eukaryotic and prokaryotic proteins.   
 Many different host/vector systems have been used to produce antimicrobial 
peptides through recombinant DNA technology.  E. coli has been utilized most often due 
to the low cost of fermentation compared to mammalian cells, and its ability to produce 
inclusion bodies, which aid in the purification process (Haught et al, 1998).  The main 
source of success in E. coli expression of antimicrobial peptides has been through the use 
of fusion proteins, which are large proteins composed of an unrelated protein fused to the 
protein of interest (Hara and Yamakawa, 1996).  This aids expression by alleviating the 
toxicity and proteolytic degradation of the expressed antimicrobial peptide.     
 
Review of Published Expression Studies  
 As mentioned previously, antimicrobial peptides are now being looked at to 
combat antibiotic resistant strains of bacteria.  Since this is very important in the medical 
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field, many scientists are trying to produce these short peptides using bacterial systems.  
Antimicrobial peptides have been successfully expressed using several different methods, 
including commercially available fusion proteins (Piers et al, 1993), N-terminal inclusion 
body forming proteins (Haught et al, 1998; Lee et al, 2000), an N-terminal anionic pre-
pro region (Zhang et al, 1998), and tandem repeats of an anionic complement and 
antimicrobial peptide (Lee et al, 1998).   
 These different methods of gene arrangement of the antimicrobial peptides were 
resorted to because of the expression problems that arose during experimentation.    
Fusion proteins were chosen based on natural proteins or portions of natural proteins that 
enhance the formation of inclusion bodies to aid in purification as well as result in the 
reduction of proteolytic degradation (Piers et al, 1993; Taguchi et al, 1994; Lee et al, 
1998).  Piers et al. (1993) used OprF, an outer membrane protein in P. aeruginosa, along 
with pre-pro defensin to inhibit proteolytic degradation and induce formation of inclusion 
bodies.  Lee et al. (1998) fused buforin II to an acidic positively charged peptide to 
mimic the natural precursor of buforin II.  The gene encoding this anionic/cationic 
peptide complex was then multimerized and expressed at a yield of 107 mg/L active 
peptide.  Ponti et al. (1999) used a C-terminal fusion of GABA-transaminase to produce 
inclusion bodies and decrease proteolytic degradation. Haught et al. (1998) utilized 
bovine prochymosin to decrease toxicity of the antimicrobial peptide and induce 
inclusion bodies. Zhang et al. (1998) experimented with different combinations of an 
anionic stabilizing fragment and an anionic pre-pro sequence (HNP-1) to successfully 
express several antimicrobial peptides including indolicidin.     
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There are hundreds of different antimicrobial peptides and each one may be active 
in different ways against different microorganisms.  Only a few peptides have been 
produced using recombinant DNA techniques (Table 2) including cecropin A (Andersons 
et al, 1991; Hellers et al, 1991); defensin A (Reichhart et al, 1992); CEME, a cecropin-
melittin hybrid (Piers et al, 1993); apidaecin (Taguchi et al, 1994); moricin (Hara et al, 
1996); magainin P2 (Haught et al, 1998); buforin II (Lee et al, 1998); bactenecin and 
indolicidin (Zhang et al, 1998); esculentin-1 (Ponti et al, 1999); MiAMP1 (Harrison et al, 
1999); and MSI-344 (Lee et al, 2000).  PGQ has not been produced recombinantly, and 
as mentioned above, shows activity in a wide range of microorganisms.  
Although it has been proven that antimicrobial peptides can be produced in vivo, 
it is unclear if they can be produced in large quantities due to their toxicity to the host 
organism.  Yield of active protein produced by various expression systems varies due to 
the variety of methods for protein expression and purification.  The purified active 
peptide concentration of esculentin-GABA-T (Ponti et al, 1999) and MetP2 (Haught et al, 
1998) was 0.5-1 mg/L.  This fusion protein was produced in a 1 L shake flask culture and 
inclusion bodies purified by RP-HPLC.  MSI-344 (Hwang et al, 2001) expressed 310 
mg/L of active purified peptide using a 1 L fermentor grown to a high cell density before 
induction, followed by 12 hours of growth after induction.  MMIS-Buforin II (Lee et al, 
1998) was expressed at 107 mg/L of purified buforin II using a 30 L fermentor and a high 
cell density and long induction time.  These variations in peptide expression and 
purification make methods direct comparisons of expression systems impossible.  
 
 19 
 
 Table 2 Antimicrobial Peptide Expression Systems used in the Literature 
This table depicts all the advantages and disadvantages to each antimicrobial peptide 
expression cited in the literature. AMP = antimicrobial peptide, Met = methionine 
residue, CBD = cellulose binding domain 
 
 
Although different fusion proteins and expression vectors were used in all of these 
studies, there were many similarities in the expression and purification procedures.  All 
used E. coli cells with a lac promoter, and induced expression with isopropyl β-D-1-
thiogalactopyranoside (IPTG).  The construction of the protein complexes included 
flanking methionine residues to allow release of the antimicrobial peptide by cyanogen 
bromide (CNBr) cleavage of the fusion protein.  CNBr cleavage was needed, because 
activity was not seen with the fusion protein attached (Hara and Yamakawa, 1996).   It 
was shown, that after CNBr cleavage, the activity of the antimicrobial peptide buforin II 
•Low peptide yield•Utilized C-terminal fusion 
instead of N-terminal fusion like 
all other papers
•Commercially available vector
•Plasmid not commercially 
available
•Large expression yield
•Simple design
•Low peptide yield•Fusion protein reinforces 
inclusion body formation
•Simple design
•Multiple fusion proteins needed•Multiple peptide genes used
•No yield stated, assumed low
•Plasmid not commercially 
available
•Multiple peptide genes used
•F4 fusion reinforces inclusion 
bodies
•Multimerized fusion + peptide 
genes
•Used commercial Pet21c vector
•Used anionic modified 
magainin intervening seq. for 
fusion to mask toxicity
•Needed to add pre-pro defensin 
for expression
•Used S. aureus for expression
•Used commercial  PGEX
•Reduced degredation
DisadvantagesAdvantagesRecombinant 
Peptide
Met fXa Met 
Pre   Pro             CEME                                      
Met Met 
MMIS           Buforin II                                           
Hydroxylamine Cleavage
F4                        AMP                                   
Met
Prochymosin        P2                                           
Hydroxylamine Cleavage
F4                       MSI 344                                
Met
Esculentin       GABA-T                                          
Citation
Piers et al, 
1993
Lee et al. 
1998
Hwang et al. 
2001
Zhang et al. 
1998
Lee et al. 
2000
Haught et al. 
1998
Ponti et al. 
1999
His Tag
Rep21 CBD  Pre/Pro  AMP
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was not inhibited by the homoserine residue derived from the Met residue (Lee et al, 
1998).  Hydroxylamine cleavage was also used (Lee et al, 2000; Hwang et al, 2001) to 
cleave the Asn-Gly peptide bond engineered between the fusion protein and peptide.   
 
Our Approach 
 As shown above, there are many different variables to review in order to 
successfully design a system for expressing an antimicrobial peptide.  One of the 
characteristics that make our project unique is the multimerization of the antimicrobial 
peptide itself.  As stated above, the multimerization of an anionic/cationic fusion 
increased expression levels greatly (Lee et al, 1998).  It is hypothesized that, through 
multimerization of the antimicrobial peptide itself, toxicity of the peptide to the host 
organism will be decreased by inducing non-native folding without sacrificing expression 
yields.  Utilizing multimerization to reduce toxicity to the host organism will also allow 
for a greater yield due to the expression of multiple peptides simultaneously.  This feature 
is especially important for the production of indolicidin.  As stated above, a proposed 
mechanism of action of indolicidin involves disrupting DNA synthesis after penetrating 
the cell membrane.  Production of indolicidin in E. coli occurs intracellularly and the 
peptide must therefore remain inactive with respect to DNA synthesis to ensure adequate 
expression levels.  A methionine residue will be utilized to separate the monomers to 
allow cleavage to produce an active antimicrobial monomer from the multimer by 
cyanogen bromide cleavage.   
Indolidicin and PGQ were chosen for E. coli expression because they 
demonstrated activity against a culture grown from a Navy solid waste puck.  These 
 21 
 
pucks harbor many microbes and cause a foul odor aboard Navy ships.  When a library of 
antimicrobial peptides was tested against the microbes cultured from the Navy puck 
(Mello, unpublished), 5 µg of indolicidin and PGQ generated a substantial zone of 
clearing on an agar plate overlay, while other peptides were less effective or had no 
activity at all.  
 Using multimerization techniques, a PGQ-indolicidin hybrid is also being created 
utilizing a methionine cleavage site to express and purify active PGQ and indolicidin 
together.  This active hybrid can be achieved because indolicidin and PGQ have different 
amino acid compositions (Figure 6) and different molecular weights.  This allows for 
production of a peptide cocktail.  To our knowledge, previously this has not been shown 
in the literature, nor have multimers of this PGQ-indolicidin hybrid been described. 
 
Multimerization of Peptides 
Previous Work 
 For the past decade, scientists have been working to produce synthetic spider silk 
to mimic the properties of natural silk.  One group of scientists from the Natick Soldier 
Systems Center has produced synthetic proteins that form recombinant spider silk fibers 
(Prince et al, 1995).  Their methods included multimerizing the DNA sequence for the 
silk protein repeats in order to obtain the expression of larger proteins.  This 
multimerization process is the approach taken in this thesis for the production of 
antimicrobial peptides.  Multimers of indolicidin, PGQ and indolicidin + PGQ hybrids 
(hybIP) will be produced using the methods developed with spider silk sequences.   
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Previous Natick Projects on Indolicidin and PGQ 
Richard Beckwitt and Kevin McGrath produced the preliminary work on this 
project.  Beckwitt produced the synthetic genes for Indolicidin and PGQ, and McGrath 
produced the pUC-link vector.  Their work has allowed the multimerization of indolicidin 
and PGQ for expression studies described in the present project.  Beckwitt produced 
indolicidin monomer, dimer, and trimer genes, and PGQ monomer and trimer genes in 
the pUC-link cloning vector.  
Utilizing the previously constructed monomer antimicrobial genes, 
indolicidin:PGQ hybrids were created.  The restriction sites established during the 
synthesis of the peptide  
Figure 5 Multimerization using Nhe I and Spe I Restriction Sites 
A.  Shows restriction sites Nhe I and Spe I.  These sites are cut after the first base and 
contain the same middle 4 bases.  They are able to be ligated together due to the middle 
sequence CTAG.  When they are ligated together the sequence is unable to be cut by 
either Nhe I or Spe I.  B.  When the restriction sites are ligated into the correct 
orientation, 5’-3’, they create a sequence unable to be cut by Nhe I or Spe I.  When they 
are ligated together in the incorrect orientation, 3’-5’, an Spe I site is created which can 
be determined by a restriction enzyme digestion. 
 
Nhe I 
Recognition Site
GCTAGC
Spe I
Recognition Site
ACTAGT
Correct Orientation
GCTAGC ACTAGC ACTAGT
Nhe I Spe I5’ 5’3’ 3’
GCTAGC ACTAGT GCTAGC
Nhe I Nhe ISpe I5’ 5’3’ 3’
Incorrect Orientation
A.
B.
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gene include a 5’ Nhe I site and a 3’ Spe I site (Figures 5 and 6).  If the two sites are 
ligated together in the 5’ - 3’ orientation, they can no longer be cut in the middle by either 
of these restriction enzymes.  This allows for identification of clones with the correct 
sequence for multiple peptides.   
 
Figure 6 DNA and Amino Acid Sequence of Indolicidin and PGQ 
DNA and amino acid sequences of indolicidin and PGQ including the addition of the Nhe 
I and Spe I restriction sites flanking each gene.  Methionine residues were also inserted 
outside each natural gene for the use in cyanogen bromide cleavage following protein 
expression.  Arrows indicate the positions of CNBr cleavage.
Nhe I
GCTAGC ATG ATC CTG CCG TGG AAA TGG CCG TGG TGG
Ala   Ser Met Ile    Leu    Pro    Trp   Lys    Trp   Pro    Trp    Trp      
CCG TGG CGT CGT ATG ACTAGT
Pro  Trp    Arg   Arg   Met Thr Ser
Indolicidin
PGQ
Nhe I
GCTAGC ATG GGT GTT CTG TCT AAC GTT ATC GGT TAC CTG
Ala   Ser Met Gly    Val   Leu   Ser   Asn   Val   Ile   Gly    Tyr   Leu  
AAA AAA CTG GGT ACC GGT GCT CTG AAC GCT GTT CTG 
Lys   Lys    Leu   Gly   Thr    Gly   Ala   Leu   Asn   Ala   Val   Leu
AAA CAG ATG ACTAGT
Lys   Gln    Met  Thr  Ser
CnBr Cleavage
Spe I
Spe I
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Project Goal 
The goal of this project was to successfully clone and express two active 
antimicrobial peptides, indolicidin and PGQ, in E. coli for mass production at low cost.  
Currently antimicrobial peptides are expensive to produce and are only available in small 
quantities by extraction from the host organism or by organic peptide synthesis.  
Recombinant production should produce peptides in larger quantities at a cheaper cost.  
Peptides indolicidin and PGQ were chosen due to their previously shown activities 
against Navy solid waste pucks.  These pucks harbor microbe growth and cause a foul 
odor among Navy ships.  A long range goal, outside the scope of this project, is to use 
these peptides in food preparation surfaces, antimicrobial textiles for biological agent 
decontamination, and extended wear textiles. 
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MATERIALS AND METHODS 
 
Vectors Used 
pUC-link  
pUC-link cloning vector is derived from the pUC-18 plasmid (Appendix 6), by 
engineering  N-terminal and C-terminal Xba I and Bam HI sites, as well as an N-terminal 
Nhe I site and a C-terminal Spe I site within the pUC-18 multiple cloning site (Prince et 
al, 1995) (Figure 7). The restriction site insertion was used to regulate directional cloning 
and multimerization of antimicrobial peptide genes.  Blue and white screening of 
recombinants used in the pUC-18 cloning vector was deactivated as a result of the 
restriction site insertion.  The insertion of the “link” within the lacZ gene disables future 
lacZ insertion for blue/white screening. 
Figure 7 DNA Sequence of Synthetic Adapter Inserted into pUC18 to Create pUC-link 
This sequence was inserted into pUC18 to create Nhe I, Spe I and BamHI sites in the 
cloning vector for multimerization and direct insertion into expression vectors (Prince et 
al, 1995). 
 
Expression Vectors 
Diagrams and features of the expression vectors used in this project are shown in 
Table 3.  Qiagen produces pQE vectors with a 6x His tag at the N-terminus and an 
optimized promoter-operator.   The T5 promoter and the lac operator ensure tight 
regulation of insert gene expression to prevent uninduced expression. The β-lactamase 
5’  CT AGA GGA TCC ATG GCT AGC GGT GAC CTG AAT AAC ACT AGT GGA TCC T             3’
3’              T  CCT AGG TAC CGA TCG CCA CTG GAC TTA TTG TGA TCA CCT AGG AGA TC 5’
Xba I BamHI Nhe I Spe I BamHI Xba I
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gene is incorporated into these plasmids for selection (Qiagen 2000, The Expressionist, 
pg 14).   
Novagen created the pET system for E. coli expression.  All pET vectors are 
available in three reading frames.  The plasmid contains the f1 origin of replication, and 
the T7 lac promoter using IPTG as the inducer.  pET 28a+ contains a C-terminal 6x His 
tag, T7 tag and no fusion protein.  pET 32a+ contains an internal 6x His tag and S-tag 
along with a 20 kDa N-terminal thioredoxin fusion protein.  pET 43.1 a+ contains an 
internal 6x His tag and S-tag with a N-terminal 66 kDa Nus A fusion protein.  
PGEX-4T-2, made by Pharmacia, contains the N-terminal fusion protein 
Glutathione S-transferase (GST).  This system utilizes the tac promoter and a thrombin 
cleavage site.  It is provided in all three reading frames and codes for ampicillin 
resistance and an internal lac Iq gene for use in any E. coli host (see Appendix 1-5 for all 
vector maps). 
 27 
 
 
Table 3 Expression Vectors Used in this Project 
 
E. coli Host Strains Used 
Cloning Host Strains 
The XL1-Blue cloning host strain contains genomic tetracycline resistance, which 
allows selection of only this E. coli strain.  This general-purpose propagation host strain 
enables reproduction of plasmids containing an ampicillin resistance gene (Table 4). 
 
 
 
•No fusion protein•Bam HI site in MCS
•No Nhe I or Spe I in vector
•No fusion protein
•Contains Nhe I site in vector
•Bam HI site in MCS
•No Spe I site in vector
•C-terminal and N-terminal 6x 
his tag
•Lacks T7lac promoter for toxic 
proteins
•Contains GST fusion protein
•BamHI site in MCS
•No Nhe I and Spe I sites
•Contains Spe I site in vector•Contains Nus A fusion protein
•BamHI site in MCS
•No Nhe I sites
•Contains Thioredoxin fusion 
protein
•BamHI site in MCS
•No Nhe I or Spe I sites
DisadvantagesAdvantagesVector
6x His Tag
Trx        S-tag   EK       MCS
pET32 a+
Thrombin
GST                 MCS
pGEX-4T-2
Thrombin
His Tag
NusA    S-tag   EK       MCS
pET43.1 a+
Thrombin
His Tag
pET28 a+
Thrombin
His Tag
T7 tag      MCS
6x His Tag          MCS
pQE-30
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Host Strains for Expression 
Several expression host strains were chosen (Table 4) based on antibiotic 
resistance, presence of λDE3 prophage (necessary for expression of T7 RNA polymerase) 
and demonstrated expression of antimicrobial peptides (Hwang et al, 2001).    
Table 4 E. coli Host Strains 
Host Strain Genotype Properties Company 
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17, 
supE44, relA1, lac[F’ proAB laclq 
∆ZM15 Tn10 (Tetr)]  
General purpose 
cloning host 
strain 
Stratagene 
JM109DE3 recA1, endA1, gyrA96, thi, hsdR17, (rk- 
mk+), supE44, ∆(lac-pproAB), relA1, 
[F' traD36, proAB+, lacIqZ, ∆M15] 
DE3 
N/A Promega 
BL21DE3 Derived from : B-strain, F-, 
ompT, hsdSb(rb- mb-), gal, dcm 
(DE3) 
General purpose 
expression host 
proteolytically 
deficient 
Novagen 
HMS174DE3 Derived from: K-12, F-, recA, 
hsdR(rk12- mk12+), Rifr (DE3) 
recA-, K-12 
expression host 
Novagen 
AD494DE3 Derived from: k-12, ∆ara-
leu7697, ∆lacX74, ∆phoAPvuII, 
phoR ∆malF3 F' [lacI+(lacIq)pro] 
trxB::kan (DE3) 
trxB- expression 
host, allows 
disulfide bond 
formation in E. 
coli cytoplasm 
Novagen 
NovablueDE3 Derived from: K-12, recA-, 
endA-, lacIq, gyrA96, relA1, lac 
[F' proA+B+, 
lacIqZ∆M15::Tn10(Tcr)trxB::kan 
(DE3) 
recA-, endA-, 
K-12, lacIq 
expression host 
Novagen 
M15[pREP4] and 
SG13009[pREP4] 
Derived from K-12, Nals, Strs, 
Rifs, Thi-, Lac-, Ara+, Gal+, Mtl-, 
F-, RecA+, Uvr+, Lon+ 
Expresses toxic 
proteins and 
pQE plasmid 
proteins 
Qiagen 
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Multimerization of Antimicrobial Peptides  
For multimerization, the peptide genes were cut out of the cloning vector by 
restriction enzyme digestion, ligated to each other and the cloning vector, and 
transformed into an appropriate E. coli host for production and analysis. 
The subcloning vector, pUC-link, was digested with Nhe I and Spe I by 
combining 1 µl of a solution containing 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 
mM dithiothreitol, pH 7.9, 10 µg of pUC-link, 1 µl NheI + Spe I (2:1) and 8 µl of water.  
Digestion reactions were incubated at 37 ˚C for 1 hour.  Digested DNA was analyzed by 
agarose gel containing 0.045 M Tris-borate, 0.001 M EDTA, pH 8.3, and 1.5% agarose at 
85 volts for 1 hour.  The inserts were multimerized by combining 20 µg of digested 
indolicidin or PGQ monomer, 1 µl of T4 DNA ligase (6 units), 1 µl of 50 mM Tris-HCl 
pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, 25 µg/ml bovine serum 
albumin, and 8 µl of water and incubating the reaction at 16˚ C for 16 hours.  The ligation 
was analyzed by 1.5% agarose gel electrophoresis.  
Multimerized indolicidin and PGQ inserts and linear vector bands were extracted 
from the agarose gel and purified using a Qiagen Gel Extraction Kit.  DNA was 
quantified in a 1.5% agarose gel compared to phi-X174 DNA marker.  
Linear vector was dephosphorylated by combining 10 µg of vector, 1 µl of calf 
intestinal alkaline phosphate, 1 µl of 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 
mM dithiothreitol, pH 7.9, 7 µl of water and incubating the reaction mixture at 37˚C for 1 
hour, followed by heating at 75ºC for 10 minutes to denature the enzyme.  Ethanol 
precipitation was then performed to purify the vector for ligation to the insert.  
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The multimerized inserts were ligated to the dephosphorylated cloning vector in 
reactions containing 10:1 (insert to vector), 2:1, or no insert control, 1 µl of T4 DNA 
ligase, 1 µl of a solution containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM 
dithiothreitol, 1 mM ATP, 25 µg/ml bovine serum albumin, and 8 µl of water.  Reactions 
were incubated at 16˚ C for 16 hours.  Ligated DNA was transformed into XL1-Blue cells 
(Stratagene) by adding 50 µl of chemically competent XL1-Blue cells and 2 µl of ligation 
reactions 10:1 (insert to vector), 2:1 or no insert control mixture.  The cell/plasmid 
mixture was held on ice for 30 minutes, 42°C for 90 sec, then on ice for two minutes.  An 
800 µl aliquot of SOC (20 g tryptone, 5 g yeast extract, 0.5 g NaCl per liter, autoclave, 
add 10 µl MgCl2/MgSO4 and 20 µl 20% glucose per ml) was added; the cells were then 
placed at 37°C for five minutes, and then incubated in a 37°C shaker at 250 rpm for one 
hour.  Cells (100 µl) were plated on LB (5 g yeast extract, 10 g NaCl, 10 g peptone, 15 g 
agar, per liter water) plates supplemented with 50 µg/ml of carbenicillin and 15 µg/ml of 
tetracycline.  Plates were incubated at 37°C overnight. 
 
 
Plasmid Analysis 
Several colonies were chosen and innoculated into 4 ml of LB with appropriate 
antibiotics.  Minicultures were grown overnight in a 37ºC shaker at 250 rpm.  The cells 
were pelleted at 10,000 x g for 10 minutes at 20˚C, and a Qiagen Mini Prep kit was used 
to purify the plasmid.  Plasmid DNA was cut with Bam HI to determine if an insert was 
present. The restriction digestion was done using 1 µl Bam HI (2 units), 5 µl DNA, 1 µl 
Bam HI Buffer (150 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, 
pH 7.9, 100 µg/ml BSA), and 3 µl water.  The reaction was incubated at 37°C for one 
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hour.  The digestion mixture was run on a 4-12% polyacrylamide gel (Novex) in TBE 
(10.8 g Tris base, 5.5 g Boric acid, 0.58 g EDTA, add water to 1 L and pH to 8.3) buffer 
at 200V for 30 minutes, placed in 10 µg/ml ethidium bromide for 10 minutes and 
photographed on a UV light box.   
The colonies that contained insert were digested to determine if the correct 
orientation for transcription of the multimerized insert was produced.  This was done by 
digesting the recombinant vector with both Nhe I and Spe I.  If an insert is in the correct 
orientation, then a band would be observed on the gel at the same size as the insert found 
previously with Bam HI digestion.  If the insert was not in the correct orientation, then 
the band on an agarose gel would run corresponding to the size of the monomeric gene 
size.  
All clones with the correct orientation were then sent to the Cornell DNA 
Sequencing Facility where they were sequenced using an Applied Biosystems Automated 
3700 DNA Analyzer with Big Dye Terminator chemistry and AmpliTaq-FS DNA 
Polymerase.  Sequences were analyzed with DNA Star software. 
 
Transfer of Insert from pUC-link into Expression Vector  
After the insert in pUC-link was determined to be correct by DNA sequencing, it 
was then subcloned in the expression vector.  pUC-link was designed to have a Bam HI 
site outside the Nhe I and Spe I restriction sites (Figure 7).  The pUC-Amp clone and the 
expression vector were separately digested with Bam HI.  The expression vector was 
subsequently dephosphorylated to prevent self-ligation.  The insert and dephosphorylated 
vector were then ligated using T4 DNA ligase (New England Biolabs) and transformed 
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into XL1-Blue cells for propagation.  After performing a mini-prep isolation of plasmid 
DNA, restriction digestion with Bam HI, Nhe I, and Spe I, and agarose gel 
electrophoresis confirmed the presence of an insert.   
 
In vitro Transcription/Translation 
 In order to test each expression vector/multimerized insert combination for 
expression, an in vitro transcription/translation method was initially used (Promega).  The 
reactions contained 4 µg of purified expression plasmid containing the AMP insert, 5 µl 
of minus methionine and minus leucine amino acid mixture to obtain all amino acids, 20 
µl of S30 Premix without amino acids, and 15 µl of T7 S30 circular DNA extract in a 
total volume of 50 µl.  The tubes were vortexed and centrifuged for 10 sec at 12,000 x g 
at 20˚C to settle reagents.  1 µl of Transcend biotinylated lysine tRNA (Promega) was 
added and samples were incubated at 37°C for 1 hour.  Samples were then placed on ice 
for 5 minutes to stop the reaction.  An aliquot containing 1/10 of the total volume was 
removed from the reaction and added to 20 µl acetone and incubated on ice for 15 
minutes to precipitate the protein.  The samples were spun at 12,000 x g at 20˚C in a 
microcentrifuge for 5 minutes and the supernatant was removed and discarded.  To 
remove the remaining acetone, the samples were lyophilized for 5 minutes.  20 µl 2X 
SDS sample buffer was added to the lyophilized protein and run on a 10% 
polyacrylamide gel with 12.1 g/L Tris Base, 17.9 g/L Tricine, 1 g/L SDS running buffer.  
Proteins were transferred electrophoretically to a PVDF membrane at 2 mA/cm2 for 1.5 
hours using 25 mM Tris base, 150 mM glycine, 10% methanol, pH 8.3 transfer buffer 
and detected using streptavidin-alkaline phosphatase conjugate that detects the 
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biotinylated lysine residues.  The membrane was washed for 1 minute in 10 ml of TBS 
(20 mM Tris-HCL pH 7.5, 150 mM NaCl) at room temperature, then blocked in 25 ml of 
TBS + 0.5% Tween 20 for 1 hour.  The membrane was incubated for 1 hour in 10 ml of 
TBS + 0.5% Tween 20 and 2 µl streptavidin–alkaline phosphatase (2 mg/ml) to detect the 
biotinylated lysine incorporated into the protein.  The membrane was washed 4X with 25 
ml of TBS + 0.5% Tween 20 and color developed using alkaline phosphatase 
development.  60 µl of 5% nitro blue tetrazolium chloride in 70% dimethylformamide, 
and 60 µl of 5% 5-bromo-4 chloro-3-indolyl phosphate in 100% dimethylformamide 
were added to 15 ml of 100 mM Tris-Cl, pH 9.5, mM NaCl, 5 mM MgCl2.  They were 
incubated  with membrane at room temperature for 5 minutes until color developed.  To 
stop the reaction, the membrane was washed in 10 ml of water and dried.   
   
In vivo Expression of Peptide 
Small Scale Expression  
Using those constructs that showed expression of the peptide after in vitro 
transcription/translation, a small-scale expression was performed based on The 
Expressionist method (Qiagen).  The expression vector and insert were transformed into 
M15, SG13009, BL21DE3, BL21DE3pLysS, AD494DE3, HMS174DE3, NovablueDE3, 
or JM109DE3 cells and plated with appropriate antibiotics.  3 ml of LB with appropriate 
antibiotics was inoculated with colonies selected from transformation plates.  These were 
grown at 37°C in a shaker at 250 rpm until reading an OD600 of 0.6 was reached.  A 60 ml 
culture of LB with antibiotics was inoculated with an aliquot of the overnight culture and 
grown at 37°C in a shaker at 250 rpm until the OD600 read 0.5-0.7.  Also, 500 µl of the 
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starter culture was added to 500 µl of 50% glycerol and placed at -80°C for storage.  
When the culture reached mid log phase, 20 ml was removed as uninduced control and 
the OD600 was taken.  This uninduced control sample was spun at 10,000 x g for 10 min 
at 4˚C in a centrifuge to pellet the cells.  The supernatant was removed by aspiration, and 
the pellet placed at -20°C for storage.  The remaining culture was induced to a 1 mM 
final concentration (40 µl) of IPTG and placed back in 37°C shaker at 250 rpm for 3 
hours.  20 ml samples were taken out at 1.5 hrs and 3 hrs and the OD600 was taken.  They 
were pelleted at 10,000 x g for 10 min at 4˚C and the supernatant was aspirated off.  The 
pellet was placed in -20°C until the samples were ready for lysis. 
The uninduced control and induced samples were removed from the -20°C 
freezer.  An amount of Buffer A (6 M Guanidine, 100 mM NaH2SO4, 10 mM Tris pH 8) 
determined by 0.7 mls/OD600 was added to the pellet to normalize the sample protein 
concentrations. They were vortexed until the entire cell pellet was in solution.  All 
samples were centrifuged at 15,000 x g for 20 minutes at 4˚C to pellet cell debris, and 
supernatant was removed to a fresh tube.  
 Each construct and host strain lysate was analysed by western blot to determine 
which host strain had the largest yield.  The samples were run on 4-12 % SDS-PAGE and 
blotted electrophoretically using semi-dry transfer in 25 mM Bicine, 25 mM Bis-Tris, 
1.025 mM EDTA, and 0.05 mM Chlorobutanol onto PVDF membrane at 2 mA/cm2 for 
1.5 hours.  The membrane was removed from the apparatus and placed into 25 ml of 10 
mM Tris-Cl pH 8, 150 mM NaCl (TBS), 0.1% Tween 20, and 1% Gelatin for 15 minutes 
at room temperature.  The buffer was removed and incubated in antibody for the S-tag 
conjugated with alkaline phosphatase (Novagen).  10 mls of TBS + 0.1% Tween 20 and 
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1/10,000 antibody was incubated with the membrane at room temperature for 15 minutes.  
The membrane was washed four times with 25 ml of TBS + 0.1% Tween 20.  Alkaline 
phosphatase detection was performed as stated above. 
The samples with the greatest yield were nickel purified to extract only the 
product of interest from the cell lysis.  This was done by adding 100 µl of 50 % Ni/NTA 
resin equilibrated in Buffer B (8 M Urea, 100 mM NaH2PO4, 10 mM Tris pH 8) to 400 µl 
sample and placing it on a rocker for 1 hr at room temperature.  The nickel resin was then 
added to a 10 cm tall column with a diameter of 1 cm.  The flow through was collected in 
a 1.5 ml microfuge tube.  The nickel was then washed with 25 x resin bed volume (1250 
µl) Buffer C (8 M Urea, 100 mM NaH2SO4, 10 mM Tris pH 6.3).  The wash samples 
were collected in 1.5 ml microfuge tubes, and A280 was taken in a spectrophotometer until 
the fraction reached A280 ~0.01.  The protein of interest was eluted with 3 column 
volumes of Buffer E (8 M Urea, 100 mM NaH2SO4, 10 mM Tris pH 4.5) in a 1.5 ml 
microfuge tube.  The eluted sample was then analyzed by SDS-PAGE.     
 
Large Scale Expression and Purification 
 Once the construct and host strain with the highest expression yield were chosen, 
a larger scale expression culture was performed.  A 3 ml starter culture of LB with 
appropriate antibiotics was inoculated with the glycerol stock of the bacteria with 
construct.  This was grown for 8 hrs in 37°C until the OD600 reached 0.6.  One liter of LB 
with appropriate antibiotics was then inoculated with the 3 ml starter culture and grown 
to an OD600 of 0.6.  A 20 ml sample was removed for the uninduced control and pelleted 
at 10,000 x g for 10 minutes at 4˚C.  The culture was induced with IPTG at a final 1 mM 
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concentration.  This was grown for 3 hours at 37°C in a shaking incubator at 250 rpm.  
The cells were harvested in 250 ml Oakridge tubes and centrifuged for 10 min at 10,000 
x g at 4˚C.  The supernatant was removed and the pellet was placed at -20°C. 
 The cell pellet was thawed and lysed at a volume 1/50 of culture volume with a 
solution containing 6 M guanidine chloride (GuCl), 100 mM sodium phosphate 
(NaH2PO4), 10 mM Tris pH 8.0.  The pellet was resuspended by vortexing, and pelleted 
at 15,000 x g for 20 minutes at 4˚C.  The supernatant was removed and placed into a new 
tube.   
 The lysate was purified using a 12.5 cm high x 1.5 cm diameter nickel resin 
column.  The 16 ml of lysate was bound to 4 ml of a 50% slurry of nickel resin 
equilibrated in 8 M urea, 100 mM NaH2PO4, 10 mM Tris base, pH 8.0.  This optimum 
lysate:resin ratio was determined by testing volume ratios of 1:1 lysate to resin, 2:1, 4:1 
and 10:1.  A ratio of 4:1 was able to bind all available protein and elute the most purified 
sample.  The bound resin/lysate mixture was added to the column after mixing for 1 hour 
at room temperature.  2 x 16 ml of wash buffer (8 M urea, 100 mM NaH2PO4, 10 mM 
Tris base pH 6.3) was placed over the packed column and collected in 1.5 ml tubes.  The 
absorbance at 280 nm was monitored to determine when all of the unbound protein was 
washed off.  To elute, 6 ml 8 M urea, 100 mM NaH2PO4, 10 mM Tris pH 4.5 was placed 
over the column and collected.  Two more elutions were performed using 2 ml elution 
buffer.  The lysate, flow through, final wash sample, and all the elution samples were 
then analyzed by SDS-PAGE.   
 
 
 37 
 
BCA Protein Assay 
 Following purification, a BCA protein assay was performed to determine the 
concentration of the purified protein.  2 ml cuvettes were filled with 100 µl of sample and 
2 ml of a 1:50 ratio of reagent A (4% cupric sulfate) and reagent B (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid, sodium tartrate in 0.1 M sodium hydroxide) from 
Pierce were added.  Bovine serum albumin was used as a standard.  50 µl of purified 
protein was placed in a cuvette with 50 µl water and mixed.  Then 2 ml BCA solution 
was added and incubated at 37°C for 30 minutes.  Absorbance at 562 nm was read and 
the results of the standards were plotted using Excel.   
Densitometry was performed following the BCA using SDS-PAGE to determine the 
percentage of each band within a given sample.  Total Lab software was used for these 
calculations.  The amount in each band was calculated based on the total protein amount 
loaded per lane and the percentage of each band run on SDS-PAGE. 
 
Cyanogen Bromide Cleavage of Purified Product 
Once nickel purification was completed and the concentration of the products was 
determined, cyanogen bromide (CNBr) cleavage was performed.   The purified sample 
was first dialyzed to remove urea from the elution buffer.  The sample was placed in 
12,000-14,000 MW dialysis tubing 1.6 mm in diameter, and dialyzed against 50 volumes 
of 100 mM NaH2PO4 + 10 mM Tris pH 7.4 for 1 hr, and then the buffer was changed.  
This was repeated twice and the final buffer exchange equilibrated overnight. The sample 
in the dialysis tubing was removed and placed in a 1.5 ml tube.  The tube was centrifuged 
at 12,000 x g for 10 minutes at 20˚C and the supernatant removed.  An aliquot of the 
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supernatant was run on a 4-12% Bis-Tris NuPAGE Gel for analysis.  The insoluble pellet 
was dissolved in 50 µl of 50 mg/ml CNBr + 70% formic acid.  The sample tube was 
wrapped in aluminum foil and placed on a rocker for 24 hours.  To halt cleavage, the 
sample was placed in a speed-vac to remove CNBr and formic acid for 30 minutes.   
 The CNBr treated sample pellet was solubilized in 400 µl of 10% acetonitrile and 
clarified by centrifugation at 12,000 x g for 10 minutes at 20˚C and the supernate 
removed.  Both the supernatant and insoluble pellet was run on SDS-PAGE for analysis.  
Densitometry was performed on the soluble fraction using Total Lab software.  The 
percentage of monomeric peptide in the sample was calculated based on the number and 
intensity of bands.  A BCA was performed to determine the concentration of total protein 
produced upon CNBr cleavage.   
 
Amino Acid Analysis 
Multimerized and CNBr cleaved Ind3 was sent to Commonwealth 
Biotechnologies for Amino Acid Analysis.  10 µg of peptide was run on an 4-12 % SDS-
PAGE gel and blotted onto 0.45 µm PVDF membrane using a semi-dry blotting 
apparatus and 1X NuPAGE transfer buffer (20 mM Bicine, 25 mM Bis-Tris, 4.1 mM 
EDTA, 0.2 mM Chlorobutanol pH 7.2) for 1.5 hours at 2 mA/cm2.  The membrane was 
stained with 40% Methanol, 0.2% Coomassie Brilliant blue R-250 for 20 minutes and 
destained in 100% Methanol.  The bands were excised and placed in a 1.5 ml tube and 
100 µl 100% Methanol was added to completely destain the bands.  The membranes were 
placed in the speed vacuum for 5 minutes to dry.  They were sent to Commonwealth 
Biotechnologies where the membrane pieces were weighed, cut into small pieces and 
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transferred into pyrolyzed tubes.  The samples were hydrolyzed in gas phase 6 N HCl for 
90 minutes at 150ºC.  Following hydrolysis the samples were taken to dryness, and the 
amino acids present were extracted in 100 µl of 40% Methanol, 0.1 N HCl in HPLC 
water overnight with occasional vortexing.  The extract was combined with a 50 µl rinse 
of the tube containing the hydrolyzed sample.  The extract was taken to dryness, 
dissolved in 75 µl of sample loading buffer, and 5 µl of the undiluted sample was 
subjected to analysis. 
The pmol amount of each amino acid determined by Commonwealth 
Biotechnologies was compared to the expected composition of the peptide based on the 
amino acid sequence.  This was performed on an Excel spreadsheet. 
 
Antimicrobial Activity  
 E. coli 0157, E. coli 45827, S. aureus, S. typhimurium,  S. epidermidis, and 
bacteria cultured from Navy food pucks, were all tested for antimicrobial growth 
inhibition by  indolicidin and PGQ purchased from Sigma.  A plate overlay was 
performed using MH agar plates (8.75 g acid hydrolysate of casein, 1 g beef extract, 0.75 
g starch, 10 g NaCl, 7 g Noble agar, H2O to 500 ml and autoclave) and M9 agar plates 
(M9 salts 10X = 15 g Na2HPO4, 7.5 g KH2PO4, 1.2 g NaCl, 2.5 g NH4Cl, H2O to 250 ml.  
Add 20 ml M9 salts, 3g Bacto agar and 175 ml of H2O and autoclave).  Media was cooled 
to 55-60ºC and 0.2 ml of 1 M MgSO4, 2 ml of 10 mM CaCl2, 2 ml of 20% glucose, 0.2 
ml of 10 mg/ml thiamine and sterile H2O were added to 200 ml) and poured into plates.  
Sigma peptide dissolved to a concentration of 0.5 mg/ml in water was spotted onto a plate 
in amounts of 5, 10, and 25 µg for each bacterium.  7 ml of top agar (same recipe as 
 40 
 
plates with ½ the amount of agar) was autoclaved for 1 minute to melt the agar and 
cooled to 60ºC.  70 µl of an overnight culture of each strain was placed in the top agar, 
vortexed and poured over the plate.  The agar was allowed to dry and plates were placed 
in 37ºC incubator overnight. 
 The CNBr cleaved sample was tested for activity after determination of monomer 
concentration by BCA and densitometry.  The cleaved sample was placed in the speed 
vac to concentrate it in order to load 25 µg of peptide monomer on the test plate.  20 µl of 
peptide solution was spotted onto an MH agar plate along with 20 µl of 10% acetonitrile 
and 20 µl containing 10 µg of indolicidin from Sigma.  70 µl of an overnight culture of 
Navy puck bacteria was placed in 7 ml of MH top agar after cooling to 60ºC.  The top 
agar was poured over the plate and allowed to cool.  The plate was placed at 37ºC 
overnight to form a lawn of bacteria and analyzed for zones of clearing. 
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RESULTS 
 
The goal of this project was to successfully clone and express two antimicrobial 
peptides, indolicidin and PGQ in E. coli for mass production at low cost.  These peptides 
will then be used in food preparation surfaces, antimicrobial textiles for biological agent 
decontamination, and extended wear textiles. 
  
Figure 8 Multimerization of Antimicrobial Peptide Genes 
The antimicrobial peptide genes are multimerized by utilizing the Nhe I and Spe I 
restriction sites.  To determine if the multimerization resulted in the correct orientation 
for expression, the inserts were digested with Nhe I and Spe I.  If they are in the correct 
orientation, each monomer will not be released from the insert, where as if they are in the 
wrong orientation, monomeric units will be seen by agarose gel electrophoresis.   
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 42 
 
Multimerization of Antimicrobial Peptides via DNA Cloning 
Several multimers of indolicidin and PGQ encoding DNAs were created, along 
with several hybrid DNAs encoding indolicidin:PGQ multimeric genes.  Previous work 
created indolicidin monomer, dimer, and trimer genes, and PGQ monomer, dimer and 
trimer genes.  Utilizing the methods described (Figure 8) and previously created 
constructs, Ind6, PGQ6, hybIP (not indicated in gel), hybIPP (not indicated in gel) and 
hyb(IP)2 were created and placed into pUC-link for propagation.  Figure 9 shows the sizes 
of several DNA multimers cut with Bam HI to remove the entire cloned insert.       
 
Figure 9 Determination of Correct Insertion of Multimerized DNA Insert 
Agarose gel analysis of multimerized antimicrobial peptide genes cloned into pUC-link.  
All samples are digested with BamHI and run on a 1.5% agarose gel to determine if they 
are the correct size.  All samples shown were of correct size.  Lane 1 PGQ1 , lane 2 
PGQ3, lane 3 PGQ6, lane 4 Ind1, lane 5 Ind3, lane 6 Ind6, lane 7 + 8 Hyb(IP)2, M is Phi 
X 174 marker (NEB).  
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PGQ 6
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Cornell DNA Sequencing Results 
Following insert size verification of each plasmid construct (Figure 9), 
sequencing was performed to determine if the gene contained any mutations.  The inserts 
were also sequenced again after placement of the peptide-coding insert into the 
expression vector (Figure 10) to verify that the DNA was in the correct reading frame.  
The results were analyzed with DNA Star software.  All sequences conformed to the 
expected outcome (See Appendix 7-13). 
      
Expression in pQE-30  
Small-scale in vivo expression (inducing a small culture of cells using IPTG) (Figure 10) 
was used to determine if the plasmids encoding multimerized antimicrobial peptides were 
expressed in both M15 and SG13009 cells.  Expression was tested with pQE-30:PGQ3 
(trimer), which should produce a 12 kDa protein.  The plasmid pQE-40 containing a 
dihydrofolate reductase gene (DHFR 26 kDa) was used as a positive expression control.  
Figure 11 represents an SDS-PAGE depicting the expression levels of DHFR and PQE-
30:PGQ3.  Under induction conditions, even in the complex mixture, DHFR can be seen 
above all other background proteins (lanes 3,8,9).  However, no evidence of 12 kDa 
PGQ3 expression was obtained in this expression system (lanes 6, 7, 11, 12).   Expression 
was tested with pQE-This small-scale expression of pQE-30:PGQ3 was performed 
multiple times with the same negative result (Figures 11 + 12).  Both cell lysate (Figure 
11) and nickel purified samples (Figure 12) were run on SDS-page gels to determine if 
PGQ3 was expressed.  Only the induced positive control showed a band around 26 kDa.   
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Figure 10 Cloning and Expression of Multimerized Antimicrobial Peptide Genes in E. coli 
After creation of AMP multimer gene, it was inserted into pUC-link and propagated.  
Inserts found to be in the correct orientation were extracted by BamHI digestion and 
inserted into an expression vector.  It was then transformed into an expression host strain 
and expression was induced with IPTG to produce the recombinant multimerized peptide.  
The multimeric peptide was cleaved with cyanogen bromide to created monomeric 
peptide.  
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Figure 11 SDS-PAGE Analysis of Cell Lysates 
Cell lysates of small-scale expression of pQE-30 with PGQ 3 insert in host strains 
SG13009 and M15 induced and uninduced samples.  Only expression of the positive 
control pQE-40 with DHFR protein was observed.  No expression of PGQ 3 was seen.  M 
= mark-12 molecular weight marker; lane 2 uninduced SG13009 pQE-40; lane 3 induced 
SG13009 pQE-40; lane 4 uninduced SG 13009 pQE-40; lane 5 uninduced SG13009 
pQE-30:PGQ3; lane 6 induced SG13009 pQE-30:PGQ3; lane 7 induced SG13009 pQE-
30:PGQ3; lane 8 induced M15 pQE-40; lane 9 induced M15 pQE-40; lane 10 uninduced 
M15 pQE-30:PGQ3; lane 11 induced M15 pQE-30;PGQ3; lane 12 induced M15 pQE-
30:PGQ3.  
 
DHFR (26 kDa)
PGQ3+ control + control PGQ3
SG13009 M15
Lane    M     2    3     4  5    6     7      8      9    10  11   12
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3.5 kDa
66.3 kDa
55.4 kDa
0      +       0        0        +       +        +       +     0        +        +        Induction
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Figure 12 SDS-PAGE Analysis of Nickel Purified Protein 
Nickel purification of pQE-30 PGQ 3 small-scale expression in SG13009 and M15 host 
strains.  After purification only pQE-40 DHFR positive control showed expression as 
predicted with a 26 kDa protein and purification using 6x His tag. No PGQ 3 was 
expressed. M = mark 12 molecular weight marker; lane 2 SG13009 uninduced pQE-40; 
lane 3 SG13009 induced pQE-40; lane 4 SG13009 induced pQE-40 no expression of 
DHFR; Lane 5 SG13009 uninduced pQE-30:PGQ3; lane 6 SG13009 induced pQE-
30:PGQ3; lane 7 SG13009 induced pQE-30:PGQ3; lane 8 M15 induced pQE-40; lane 9 
M15 induced pQE-40; lane 10 M15 induced pQE-30:PGQ3; lane 11 M15 induced pQE-
30:PGQ3; lane 12 M15 induced pQE-30:PGQ3.  
 
Expression in Other Host Strains 
 Due to the lack of expression of pQE-30:PGQ3, another non-fusion expression 
vector, pET28a+, was used to test for expression.  Both PGQ3 and PGQ6 were placed 
into the expression vector and small-scale expression performed.  Unfortunately with 
pQE-30, no expression was achieved under conditions that strongly expressed DHFR 
(data not shown).  Due to this result, fusion proteins were explored as an alternate means 
Lane    M     2      3     4  5     6      7      8     9   10   11   12
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97.4 kDa
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of expression based on data from peer-reviewed journals.  Several fusion protein 
expression vectors were available that should produce peptide in the correct reading 
frame.  These vectors included pET32a+ with a thioredoxin fusion, pET43.1a+ with a 
NusA fusion, and pGEX-4T-2 containing a GST fusion.  Due to the large number of 
multimerized inserts created and the variety of vectors available, it was decided to 
perform in vitro transcription/translation to quickly determine which expression vectors 
produce the recombinant peptide. 
 
In vitro Transcription/Translation 
The constructs were tested by in vitro transcription/translation with biotinylated 
lysine tRNA using streptavidin-alkaline phosphatase to determine if expression was 
possible.   
Table 5 Vectors and Inserts used for In Vitro Transciption/Translation 
In vitro transcription/translation resulted in all inserts within pET32a+ and PGQ 6 in 
pET43.1a+ expressing the correct size peptide.   
NoPGQ 6merpGEX-4T-2
GST fusion
Yes
No
No
PGQ 6mer
Indolicidin 3mer
(Indolicidin + PGQ)2
pET43.1a+
NusA fusion
Yes
Yes
Yes
PGQ 6mer
Indolicidin 3mer
(Indolicidin + PGQ)2
pET32a+
Thioredoxin fusion 
(Trx)
No
No
No
PGQ 3mer
Indolicidin 1mer
PGQ 1mer
pET28a+
NoPGQ 3merpQE-30
In Vitro
Expression
AMP InsertExpression 
Vector
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The results of this in vitro expression experiment (Table 5) confirmed that both pQE-30 
and pET28a+ did not express PGQ3 (data not shown).  The inserts were placed into 
pET28a+ and tested for in vitro expression (Table 5).  In contrast to the negative data 
obtained with non-fusion proteins, several expression vectors containing the fusion 
protein displayed positive expression in vitro.   
 The in vitro reactions were analyzed by detection of biotinylated protein products 
to determine if the predicted protein size is present after translation.  A protein product of 
the appropriate size was detected with the fusions (Figure 13 lanes 3, 4, 5, 6) 
NusA:PGQ6, Trx:PGQ6, Trx:Ind3, and Trx:hyb(IP)2.  However, no product was seen 
with GST:PGQ6 or pET28:PGQ6 (lanes 7 and 8). 
Figure 13 In Vitro Transcription/Translation Results 
The end product from in vitro transcription/translation was run on SDS-PAGE and 
blotted electrophoretically onto PVDF membrane.  Streptavidin conjugated alkaline 
phosphatase was incubated with the membrane and exposed to alkaline phosphatase color 
development showing all biotinylated proteins expressed in vitro.  M = biotinylated 
protein marker; Lane 1 – control no vector; Lane 2 + control pinpoint vector (Promega) 
with 39 kDA band; Lane 3 NusA:PGQ6 showing 85 kDa band; Lane 4 Trx:PGQ6 
showing 40 kDa band; Lane 5 Trx:Ind3 showing 29 kDa band; Lane 6 Trx:hyb(IP)2 
showing 32 kDa band; Lane 7 GST:PGQ6 showing no bands corresponding to predicted 
45 kDa; Lane 8 pET28:PGQ6 showing no 26 kDa band. 
Trx:hyb(IP)2 (32 kDa)
Trx:Ind3 (29 kDa)
Lane   M   1    2    3     4    5     6    7    8   M 
105 kDa
37.5 kDa
46.5 kDa
NusA:PGQ6 (85 kDa)
Trx:PGQ6 (40 kDa)
28 kDa
20.5 kDa
6.5 kDa
57 kDa
76 kDa
165 kDa
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In vivo Expression in Different Host Strains 
 The vectors demonstrating positive in vitro expression were transformed into 
several E. coli host strains to evaluate in vivo expression levels.  The host strains were 
chosen based on vector compatibility, proteolytic deficiency, and citations in peer-
reviewed journals.  Five host strains were chosen and compared by small-scale 
expression and western blots.  For comparison, (Figures 14-17) the amount of lysate 
loaded on SDS-PAGE were normalized based on optical density at each sample 
collection.  All constructs contained an S-tag for antibody and alkaline phosphatase 
detection.  The results in Figures 14-17 show that BL21DE3 (lanes 2 & 3) and 
AD494DE3 (lane 4 & 5) show the greatest expression yield.  All host strains expressed 
the antimicrobial gene, but some weren’t as efficient as others.  Ultimately BL21DE3 and 
AD494DE3 were chosen to carry on further experiments with purification of the protein 
based on the intensity of the western blot bands including NusA:PGQ6, Trx:Ind3, and 
Trx:(IP)2. 
 50 
 
Figure 14 Expression of Trx:PGQ6 in Various Host Strains 
Small-scale expression of Trx:PGQ6.  The sample was run on 4-12% SDS PAGE, 
electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and 
alkaline phosphatase detection.  BL21DE3 and AD494DE3 cells showed the greatest 
expression level after 1.5 hours of induction.  Lane 1 Trail Mix Western Markers; Lanes 
2 and 3 BL21DE3 after 1.5 and 3 hours of induction shows expression; Lanes 4 and 5 
AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 7 
HMS174DE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 8 and 
9 NovablueDE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 10 
and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows little expression; Lane 
12 pET32a+ positive control after 3 hours shows predicted 20 kDa band.   
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Figure 15 Expression of NusA:PGQ6 in Various Host Strains 
Small-scale expression of NusA:PGQ6.  The sample was run on 4-12% SDS PAGE, 
electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and 
alkaline phosphatase detection.  Lane 1 Trail Mix Western Markers; Lanes 2 and 3 
BL21DE3 after 1.5 and 3 hours of induction shows little expression; Lanes 4 and 5 
AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 7 
HMS174DE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 8 and 
9 NovablueDE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 10 
and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows little expression; Lane 
12 pET43.1a+ positive control after 3 hours shows predicted 65 kDa band.   
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Figure 16 Expression of Trx:Ind3 in Various Host Strains 
Small-scale expression of Trx:Ind3.  The sample was run on 4-12% SDS PAGE, 
electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and 
alkaline phosphatase detection.  BL21DE3 and AD494DE3 cells showed the greatest 
expression level after 1.5 or 3 hours of induction.  Lane 1 Trail Mix Western Markers; 
Lanes 2 and 3 BL21DE3 after 1.5 and 3 hours of induction shows expression; Lanes 4 
and 5 AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 
7 HMS174DE3 cells after 1.5 and 3 hours of induction show no expression of predicted 
29 kDa band; Lanes 8 and 9 NovablueDE3 cells after 1.5 and 3 hours of induction shows 
no expression; Lanes 10 and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows 
no expression; Lane 12 pET32a+ positive control after 3 hours shows predicted 20 kDa 
band.   
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Figure 17 Expression of Trx:hyb(IP)2 in Various Host Strains 
Small-scale expression of Trx:hyb(IP)2.  The sample was run on 4-12% SDS PAGE, 
electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and 
alkaline phosphatase detection.  BL21DE3 and AD494DE3 cells showed the greatest 
expression level after 1.5 or 3 hours of induction.   Lane 1 Trail Mix Western Markers; 
Lanes 2 and 3 BL21DE3 after 1.5 and 3 hours of induction shows expression; Lanes 4 
and 5 AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 
7 HMS174DE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 8 
and 9 NovablueDE3 cells after 1.5 and 3 hours of induction shows little expression; 
Lanes 10 and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows no expression 
of the predicted 32 kDa band; Lane 12 pET32a+ positive control after 3 hours shows 
predicted 20 kDa band.   
 
 
Expression and Purification of Selected Constructs and Host Strains  
Based on the above observations, the conditions chosen for scale-up of expression 
were BL21DE3 and AD494DE3 cells induced for 3 hours.  1 L cultures expressing 
NusA:PGQ6, Trx:Ind3, and Trx:hyb(IP)2 were grown for 3 hrs and purified using a 
Ni/NTA column.   Figure 18 shows very strong expression of Trx:Ind3 (lanes 4 & 5) with 
only minor contaminants after column purification (lane 5). 
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Figure 18 SDS-PAGE of NusA:PGQ6, Trx:Ind3, Trx:hyb(IP)2 Cell Lysates and Nickel Purified. 
NuPAGE 4-12% Bis-Tris gel of large-scale expression lysates.  Gel was stained with 
coomassie blue.  Trx:Ind3 showed the greatest expression yield.  Lane 1 M12 marker; 
Lane 2 NusA:PGQ6 cell lysis sample; Lane 3 NusA:PGQ6 purified sample; Lane 4 
Trx:Ind3 cell lysis sample; Lane 5 Trx:Ind3 purified sample; Lane 6 Trx:hyb(IP)2 cell 
lysis sample; Lane 7 Trx:hyb(IP)2 purified sample 
   
Cyanogen Bromide Digestion of Purified Product 
The presence of Met residues allows separation of the Ind multimers by cyanogen 
bromide cleavage (Figure 19).  A CNBr digest was performed on nickel purified Trx:Ind3 
to cleave the multimerized peptide/fusion protein and obtain indolicidin monomer (Figure 
20).   
Trx:Ind3
Trx:hyb(IP)2
NusA:PGQ6
Lane 1 2 3    4    5    6    7   
200 kDa
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97.4 kDa
66.3 kDa
55.4 kDa
NusA:PGQ6 Trx:Ind3 Trx:hyb(IP)2
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Figure 19 Cyanogen Bromide Cleavage Site in Multimerized Peptide 
Met labeled arrows indicate where the multimeric peptide is cleaved by cyanogen 
bromide treatment. 
Figure 20 CNBr Cleavage of Trx:Ind3 
CNBr cleaved Trx:Ind3 sample run on NuPAGE 4-12% Bis-Tris gel and stained with 
coomassie.  Ind1 shows correct size decrease after CNBr cleavage.  Lane 1 represents 
M12 molecular weight Marker; Lane 2 represents CNBr cleaved Trx:Ind3 (predicted size 
of Ind monomer is 2.0 kDa); Lane 3 represents uncleaved TrxInd3 (predicted size is 29 
kDa). 
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Prior to CNBr cleavage, the 8 M Urea was dialyzed from purified samples to precipitate 
the protein product.  Products of CNBr cleavage were analyzed by SDS-PAGE (Figure 
20).  Although larger products were also obtained due to cleavage of the fusion protein, a 
product of the correct size for Ind monomer was observed.   
Several different buffers including 20 mM Tris pH 7.5, 6 M guanidine, 30% 
acetonitrile, and 10% acetic acid were tested to solubilize the pelleted product after 
cleavage based on literature descriptions (Ponti et al, 1999; Haught et al, 1998; Lee et al, 
1998).  Each buffer solution was tested for antimicrobial activity to determine if they 
could be used for activity assays by bacterial overlays.  Ten percent acetic acid was the 
only solution to show any antimicrobial activity and thus was not used for 
resolubilization.  The concentrations of acetonitrile and Gdn-HCl were decreased to 10% 
and 4 M respectively due to their incompatibility with the BCA protein assay performed 
prior to the antimicrobial activity assay.  Ten percent acetonitrile was chosen for 
solubilization because 20 mM Tris did not solubilize the peptide completely, and 4 M 
guanidine became insoluble upon concentrating the sample, due to the large volume 
needed for solubilization.  
 A BCA protein assay and gel densitometry of the CNBr cleaved solubilized 
product were performed to predict the amount of monomer produced per ml of dialyzed 
nickel purified product.  The concentration of the entire cleaved sample ranged from 0.3 
to 0.7 µg/µl in a 600 µl sample of solubilized product.   
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Amino Acid Analysis 
Amino acid analysis was performed by Commonwealth Biotechnologies on the 
Trx:Ind3 nickel purified protein product.  Tryptophan is unable to be detected using the 
acid hydrolysis method of amino acid analysis, thus resulting in a large discrepancy in the 
percent difference reported in Table 6.  All other amino acid percentages were within 
range of the predicted composition. 
Table 6 Amino Acid Analysis Trx:Ind3 Purified Sample 
*Cys and Trp cannot be detected by the hydrolysis performed.  Observed Cys is actually 
Cystine detected. 
 
Quantitation 
 Quantitation of yield of nickel purified and cyanogen bromide treated Trx:Ind3 
was determined based on BCA assays and densitometry.  Following nickel purification, a 
BCA was performed to determine the total protein concentration.  Densitometry was then 
performed using Total Lab software after running the nickel purified sample by SDS-
Amino Acid % Comp Actual % Comp observed Difference
ASX 9.1% 8.5% 0.6%
GLX 4.9% 6.1% -1.2%
CYS 0.8% 2.8% -2.0%
ALA 7.2% 7.3% -0.1%
PHE 1.9% 2.5% -0.6%
GLY 6.8% 8.0% -1.2%
HIS 3.8% 2.1% 1.7%
ILE 6.1% 5.2% 0.9%
LYS 6.8% 5.0% 1.8%
LEU 9.5% 9.4% 0.1%
MET 4.9% 2.4% 2.5%
PRO 8.0% 8.7% -0.7%
ARG 5.3% 8.4% -3.1%
SER 7.6% 9.4% -1.8%
THR 7.2% 7.5% -0.3%
TYR 0.8% 2.5% -1.7%
VAL 2.3% 4.3% -2.0%
Trp 6.8% 0.0%         *6.8%
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PAGE and coomassie staining (Table 7).  The calculated molecular weight of Trx:Ind3 is 
28.951 kDa.  The percentage of Ind1 within this protein by mass is 21%.  After cyanogen 
bromide cleavage, the sample was run by SDS-PAGE and coomassie staining to 
determine the actual yield of Ind1.  Upon densitometry, the Ind1 band was determined to 
be from 24-46% of the CNBr cleaved sample compared to the predicted 21% of sample.  
This predicts that there is more than 1 protein corresponding to the 2 kDa band 
comigrating with the indolicidin monomer (see Figure 20). 
 µg in 1 L cultured 
Total nickel purified protein (BCA assay) 2541.743 
% Trx:Ind3 after densitometry 90.60% 
Final amount of Trx:Ind3 2302.819 
% Ind1 of Trx:Ind3 after densitometry 21% 
Final yield of Ind1 483.5919 
Table 7 Quantitation of Indolicidin Monomer 
Quantitation is calculated based on a BCA of total protein after nickel purified sample of 
a 1 L culture followed by densitometry of sample on polyacrylamide gel.  The percent of 
Ind1 within nickel purified product is calculated based on the 2 kDa size of Ind1 as 
compared to the 29 kDa size of Trx:Ind3.       
 
Antimicrobial Activity Assay 
 Several bacterial strains and Navy solid waste puck microbes were tested to 
determine whether commercial samples of indolicidin and PGQ were active.  Only the 
Navy puck bacteria (unpublished) on MH agar exhibited a zone of clearing with less than 
25 µg of peptide; the puck bacteria required only 5 µg of commercially available 
indolicidin or PGQ for a 1 cm zone of clearing (data not shown).  E. coli 0157, E. coli 
45827, S. aureus, S. typhimurium,  and S. epidermidis  all required more than 25 µg of 
peptide, or did not show any zones of clearing with 50 µg of peptide (data not shown). 
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CNBr cleaved Trx:Ind3 solubilized in 10% Acetonitrile was tested for activity 
with the Navy puck bacteria on MH agar plates.  25 µg of monomeric peptide revealed a 
1 cm hazy zone of clearing (Figure 21, lower right), where the 10% Acetonitrile control 
did not (lower left).  These data indicates that cyanogen bromide cleaved Ind3 produces 
active peptide.  CNBr cleaved Trx control was also tested for antimicrobial activity along 
with nickel purified Trx:Ind3 to determine whether only CNBr cleaved Ind1 shows 
antimicrobial activity against the microbes cultured from the Navy puck.  No zones of 
clearing occurred with either the CNBr cleaved Trx control (Figure 22) or nickel purified 
Trx:Ind3 (data not shown). 
 
Figure 21 Plate Overlay of Cyanogen Bromide Digested Trx:Ind3 
This figure shows the zone of clearing of indolicidin from sigma (upper left) and 
recombinant indolicidin (lower right).  The 10% Acetonitrile control (lower left) showed 
no zones of clearing.  This overlay was performed using MH agar and Navy puck 
bacteria. 
Recombinant 
indolicidin 3 
cut with 
cyanogen 
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+ control 
Indolicidin 
from 
Sigma
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Figure 22 Plate Overlay of Cyanogen Bromide Digested Trx fusion protein 
This figure demonstrates no antimicrobial activity of the Trx fusion protein alone 
following cyanogen bromide cleavage.  This control is needed as cleavage of the fusion 
protein may have resulted in peptide fragments with antimicrobial activity. 
+ control 
Indolicidin 
from 
Sigma
Trx fusion 
protein 
after CNBr 
cleavage
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DISCUSSION 
 
 
Natural Indolicidin vs. Recombinant Indolicidin 
 Natural indolicidin is a 13 amino acid peptide, which is aminated at the carboxyl 
terminus (Falla et al, 1996).  The recombinant indolicidin produced by E. coli does not 
contain an aminated carboxyl terminus and contains a methionine residue at the N-
terminus.  This is a product of the cyanogen bromide cleavage utilized in the 
multimerization technique to produce indolicidin.  This methionine residue is also 
contained in the constructs of recombinant peptides described in published studies (Lee et 
al, 1998. Zhang et al, 1998. Lee et al, 2000. Ponti et al, 1999), in which it was determined 
not to affect the antimicrobial activity of the peptides produced.  Antimicrobial activity of 
recombinant indolicidin versus natural indolicidin has not been investigated prior to this 
study.  Recombinant Ind1 shows similar size zones of clearing following cyanogen 
bromide cleavage, although purification must be done in order to attribute these results to 
recombinant Ind1.  
 
Vectors and Host Strains 
 Initially only pQE-30 and pET28a+ were chosen as expression vectors for the 
multimerized peptides due to their ability to express toxic proteins fused to a 6x His tag.  
When neither of these constructs produced any recombinant protein, other expression 
systems were found by searching the literature for features of successful antimicrobial 
peptide expression systems.  Vectors expressing a fusion protein were chosen based on 
multiple articles stating that low peptide, or no peptide, was produced without a fusion 
protein (Ponti et al, 1999; Zhang et al, 1998; Harrison et al, 1999). While previous studies 
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created their own fusion proteins, the fusions we used were chosen from commercial 
vectors containing BamHI restriction sites and possessing the ability to express the 
peptides in the correct reading frame.  This resulted in choosing pET43.1a+ (Nus A 
fusion), pET32a+ (thioredoxin fusion), and pGEX-4T-2 (GST fusion).   
After selection of expression vectors, several different host strains were chosen 
from those described in the literature that produced the highest expression levels.  This 
literature search resulted in the choice of Bl21DE3 (Lee et al, 1998 and Ponti et al, 1999), 
HS174DE3 (Lee et al, 2000), and JM109 (Taguchi et al, 1994).  These host strains 
differed not only in antimicrobial peptide expression, but also in properties such as 
proteolytic deficiencies, solubilization of recombinant proteins, or derivation from 
different cell strains. 
     
In vitro Transcription/Translation 
In vitro transcription/translation was deemed necessary following the inability to 
successfully express the peptide genes in pQE-30 or pET28a+.  Although the literature 
led us to expect that low yields of peptide would be expressed even without a fusion 
protein (Zhang et al, 1998) no expression was seen.  These experiments determined that 
the only constructs expressed in vitro were those in fusion protein vectors.   
The lack of in vitro expression of the non-fusion protein vectors may be due to 
truncated expression of the peptides, or incorrect transcription or translation from the 
expression vectors.  This in vitro transcription/translation system is designed to express 
plasmids with both E. coli promoters and T7 promoters.  This was chosen because all 
pET vectors contain T7 promoters.          
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Expression and Purification of Selected Constructs 
Once the constructs were chosen for in vivo expression and purification, the 
optical density (OD) of each induced culture was monitored to determine whether cell 
growth halted or decreased following induction as seen in expression of pQE-30 and 
pET28a+ constructs.   Trx:Ind3 showed a large increase in OD during induction as 
expected of a productive culture in log phase growth.  Both Trx:hyb(IP)2 and 
NusA:PGQ6 showed a leveling off of cell growth following induction (data not shown).   
This may have resulted in the lower expression levels of those constructs.   
Cyanogen bromide cleavage originally posed a problem because the purified 
expression protein was in a solution containing 8 M urea; this affected the antimicrobial 
activity of the sample following cyanogen bromide cleavage due to formic acid 
remaining in the sample.  This was resolved by dialyzing the urea away into a non-
denaturing buffer, thus making the protein insoluble.  The cyanogen bromide digestion 
itself allowed the purified protein to become soluble in the formic acid, and all formic 
acid was removed during lyophilization.   
Another hurdle before activity could be tested included the re-solubilization of the 
cyanogen bromide cleaved peptide product.  Several solvents were tested for 
antimicrobial activity, resulting in the use of 10% acetonitrile. 
  
Quantitation 
 Comparing expression yields with those described in the literature was not 
straightforward.  Each article reviewed utilizes a slightly different method of production, 
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purification and quantitation of the peptide produced, making it difficult to directly 
compare the yield.  Quantitation of yield for the recombinant Ind1 was only theoretically 
calculated and not determined directly.  This calculation was based on BCA and 
densitometry of the nickel purified Trx:Ind3 sample of a 1L shake flask culture.  Lee et 
al. (1998), calculated a final concentration of 107 mg/L of purified antimicrobial peptide 
produced in a 30 L high cell density fermentation, based on BCA.  Haught et al. (1997) 
calculated 0.37 mg/L of purified peptide product from 1 L shake flask fermentation based 
on BCA and densitometry after solubilization of inclusion bodies, similar to the method 
used here.  This suggests that the 1 L shake flask culture yields in the literature ranging 
from 0.37-1 mg/L purified active peptide, may be directly compared to the yield of 0.5 
mg/L we obtained with Trx:Ind3.  It is hypothesized that after high cell density 
expression large yields such as those obtained by Lee et al. (1998) may be achieved with 
Trx:Ind3.  
 
Summary 
 Multimerization proved to be successful for expression of recombinant 
indolicidin. While this type of multimerization is novel for antimicrobial peptide 
production, many factors of protein expression remained similar to other studies.  As 
observed by others, the use of a fusion protein was necessary to express the peptide 
multimer.  Fusion proteins are used to hide the peptide from proteolytic cleavage as well 
as hide the toxicity of the antimicrobial peptide.  It was thought that multimerization of 
the peptide itself would be sufficient to mask the toxicity to the producing E. coli cells, 
but this was found to be untrue.  Lee et al. (1998), Ponti et al. (1999), Haught et al. 
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(1998), and Piers et al. (1993), inserted a methionine to cleave their peptide away from 
the fusion protein during purification.  Methionine residues flanking the peptide gene 
were used to cleave the multimers during purification.   
 Several differences between published literature and the multimerized peptide 
expression described here include the determination of antimicrobial activity and 
purification method.  While most peptides were purified as inclusion bodies, indolicidin 
was solubilized and passed over a Ni/NTA resin for purification via the 6x His tag.  For 
determination of antimicrobial activity, bacterial agar overlays were used by spotting 
CNBr cleaved peptide on agar plates, overlaying an agar suspension of growing bacteria, 
and looking for zones of clearing.  Only Piers et al. (1993) used a similar overlay method.  
All other published studies used liquid micro-titer plate cultures.  The main difference 
between other studies and ours was the purity of the peptide used in activity testing.  In 
our study, indolicidin monomer was not purified, while purified peptides were used in all 
other sutdies.  Purification of the CNBr cleaved sample needs to be performed to 
compare the actual concentration of recombinant indolicidin to that of natural indolicidin. 
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Appendix 1 Vector Map of pET28a+ 
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Appendix 2 Vector Map of pET32a+ 
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Appendix 3 Vector Map of pET43.1a+ 
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Appendix 4 Vector Map of pQE-30 
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Appendix 5 Vector Map of pGEX-4T-2 
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Appendix 6 Vector Map of pUC18 
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Appendix 7 Sequencing Results of Ind3 in pUC-link 
 
Ind 3 Predicted   GCTAGCATGATCCTGCCGTGGAAATGGCCGTGGTGGC 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Ind 3 Acutal     GCTAGCATGATCCTGCCGTGGAAATGGCCGTGGTGGC 
 
CGTGGCGTCGTATGACTAGCATGATCCTGCCGTGGAAA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CGTGGCGTCGTATGACTAGCATGATCCTGCCGTGGAAA 
 
TGGCCGTGGTGGCCGTGGCGTCGTATGACTAGCATGAT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
   TGGCCGTGGTGGCCGTGGCGTCGTATGACTAGCATGAT 
 
CCTGCCGTGGAAATGGCCGTGGTGGCCGTGGCGTCGTA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CCTGCCGTGGAAATGGCCGTGGTGGCCGTGGCGTCGTA 
 
TGACTAGT 
* * * * * * * 
   TGACTAGT 
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Appendix 8 Sequencing Results of Ind6 in pUC-link 
 
 
Ind 6 Predicted GCTAGCATGATCCTGCCGTGGAAATGGCCGTGGTGG 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Ind 6 Actual GCTAGCATGATCCTGCCGTGGAAATGGCCGTGGTGG 
 
CCGTGGCGTCGTATGACTAGCATGATCCTGCCGTGGA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CCGTGGCGTCGTATGACTAGCATGATCCTGCCGTGGA 
 
AATGGCCGTGGTGGCCGTGGCGTCGTATGACTAGCAT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
AATGGCCGTGGTGGCCGTGGCGTCGTATGACTAGCAT 
 
GATCCTGCCGTGGAAATGGCCGTGGTGGCCGTGGCGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GATCCTGCCGTGGAAATGGCCGTGGTGGCCGTGGCGT 
 
CGTATGACTAGCATGATCCTGCCGTGGAAATGGCCGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CGTATGACTAGCATGATCCTGCCGTGGAAATGGCCGT 
 
GGTGGCCGTGGCGTCGTATGACTAGCATGATCCTGCC 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GGTGGCCGTGGCGTCGTATGACTAGCATGATCCTGCC 
 
GTGGAAATGGCCGTGGTGGCCGTGGCGTCGTATGACT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GTGGAAATGGCCGTGGTGGCCGTGGCGTCGTATGACT 
 
AGCATGATCCTGCCGTGGAAATGGCCGTGGTGGCCGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
AGCATGATCCTGCCGTGGAAATGGCCGTGGTGGCCGT 
 
GGCGTCGTATGACTAGT 
* * * * * * * * * * * * * * * * 
GGCGTCGTATGACTAGT 
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Appendix 9 Sequencing Results of IP in pUC-link  
 
 
IP Predicted     GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTTATC 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
IP Actual GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTTATC 
 
GGTTACCTGAAAAAACTGGGTACCGGTGCTCTGAACGCT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GGTTACCTGAAAAAACTGGGTACCGGTGCTCTGAACGCT 
 
GTTCTGAAACAGATGACTAGCATGATCCTGCCGTGGAAA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GTTCTGAAACAGATGACTAGCATGATCCTGCCGTGGAAA 
 
TGGCCGTGGTGGCCGTGGCGTCGTATGACTAGTGGGATCC 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
 TGGCCGTGGTGGCCGTGGCGTCGTATGACTAGTGGGATCC 
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Appendix 10 Sequencing Results of (IP)2 in pUC-link 
 
 
(IP)2 Predicted      GCTAGCATGGGTGTTCTGTCTAACGTTATCGGTTA 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
(IP)2 Actual GCTAGCATGGGTGTTCTGTCTAACGTTATCGGTTA 
 
CCTGAAAAAACTGGGTACCGGTGCTCTGAACGCTG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CCTGAAAAAACTGGGTACCGGTGCTCTGAACGCTG 
 
TTCTGAAACAGATGACTAGCATGATCCTGCCGTGGA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
TTCTGAAACAGATGACTAGCATGATCCTGCCGTGGA 
 
AATGGCCGTGGTGGCCGTGGCGTCGTATGACTAGCA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
AATGGCCGTGGTGGCCGTGGCGTCGTATGACTAGCA 
 
TGGGTGTTCTGTCTAACGTTATCGGTTACCTGAAAAA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
TGGGTGTTCTGTCTAACGTTATCGGTTACCTGAAAAA 
 
ACTGGGTACCGGTGCTCTGAACGCTGTTCTGAAACAG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
ACTGGGTACCGGTGCTCTGAACGCTGTTCTGAAACAG 
 
ATGACTAGCATGATCCTGCCGTGGAAATGGCCGTGGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
ATGACTAGCATGATCCTGCCGTGGAAATGGCCGTGGT 
 
GGCCGTGGCGTCGTATG 
 * * * * * * * * * * * * * * * * 
 GGCCGTGGCGTCGTATG 
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Appendix 11 Sequencing Results of IPP in pUC-link 
 
IPP Predicted        GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTTA 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
IPP Actual GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTTA  
 
TCGGTTACCTGAAAAAACTGGGTACCGGTGCTCTGAA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
TCGGTTACCTGAAAAAACTGGGTACCGGTGCTCTGAA 
 
CGCTGTTCTGAAACAGATGACTAGCATGGGTGTTCTGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CGCTGTTCTGAAACAGATGACTAGCATGGGTGTTCTGT 
 
CTAACGTTATCGGTTACCTGAAAAAACTGGGTACCGGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CTAACGTTATCGGTTACCTGAAAAAACTGGGTACCGGT 
 
GCTCTGAACGCTGTTCTGAAACAGATGACTAGCATGAT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GCTCTGAACGCTGTTCTGAAACAGATGACTAGCATGAT 
 
CCTGCCGTGGAAATGGCCGTGGTGGCCGTGGCGTCGTA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CCTGCCGTGGAAATGGCCGTGGTGGCCGTGGCGTCGTA 
 
TGACTAGTGGGATCCTCTAGAGGATCCCCGGGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
TGACTAGTGGGATCCTCTAGAGGATCCCCGGGT 
 
 
 
 
 
 80 
 
Appendix 12 Sequencing Results of PGQ3 in pUC-link 
PGQ 3 Predicted   GATCCATGGCTAGCATGGGTGTTCTGTCTAACGTT 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
PGQ 3 Acutal GATCCATGGCTAGCATGGGTGTTCTGTCTAACGTT 
 
ATCGGTTACCTGAAAAAACTGGGTACCGGTGCTCT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
ATCGGTTACCTGAAAAAACTGGGTACCGGTGCTCT 
 
GAACGCTGTTCTGAAACAGATGACTAGCATGGGTG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GAACGCTGTTCTGAAACAGATGACTAGCATGGGTG 
 
TTCTGTCTAACGTTATCGGTTACCTGAAAAAACTGG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
TTCTGTCTAACGTTATCGGTTACCTGAAAAAACTGG 
 
GTACCGGTGCTCTGAACGCTGTTCTGAAACAGATG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GTACCGGTGCTCTGAACGCTGTTCTGAAACAGATG 
 
ACTAGCATGGGTGTTCTGTCTAACGTTATCGGTTAC 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
ACTAGCATGGGTGTTCTGTCTAACGTTATCGGTTAC 
 
CTGAAAAAACTGGGTACCGGTGCTCTGAACGCTGTT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CTGAAAAAACTGGGTACCGGTGCTCTGAACGCTGTT 
 
CTGAAACAGATGACTAGTGG 
        * * * * * * * * * * * * * * * * * * * 
        CTGAAACAGATGACTAGTGG 
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Appendix 13 Sequencing Results of PGQ6 in pUC-link 
PGQ 6 Predicted  GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTT 
        * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *   
PGQ 6 Actual      GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTT 
 
ATCGGTTACCTGAAAAAACTGGGTACCGGTGCTCTG 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *    
ATCGGTTACCTGAAAAAACTGGGTACCGGTGCTCTG 
 
AACGCTGTTCTGAAACAGATGACTAGCATGGGTGTT 
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *   
AACGCTGTTCTGAAACAGATGACTAGCATGGGTGTT 
 
CTGTCTAACGTTATCGGTTACCTGAAAAAACTGGGTA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *   
CTGTCTAACGTTATCGGTTACCTGAAAAAACTGGGTA 
  
CCGGTGCTCTGAACGCTGTTCTGAAACAGATGACTA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
CCGGTGCTCTGAACGCTGTTCTGAAACAGATGACTA 
 
GCATGGGTGTTCTGTCTAACGTTATCGGTTACCTGAA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
GCATGGGTGTTCTGTCTAACGTTATCGGTTACCTGAA 
 
AAAACTGGGTACCGGTGCTCTGAACGCTGTTCTGAA 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
AAAACTGGGTACCGGTGCTCTGAACGCTGTTCTGAA 
 
ACAGATGACTAGCATGGGTGTTCTGTCTAACGTTATC 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
ACAGATGACTAGCATGGGTGTTCTGTCTAACGTTATC 
 
GGTTACCTGAAAAAACTGGGTACCGGTGCTCTGAACG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
GGTTACCTGAAAAAACTGGGTACCGGTGCTCTGAACG 
 
CTGTTCTGAAACAGATGACTAGCATGGGTGTTCTGTCT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
CTGTTCTGAAACAGATGACTAGCATGGGTGTTCTGTCT 
 
 
AACGTTATCGGTTACCTGAAAAAACTGGGTACCGGTG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
AACGTTATCGGTTACCTGAAAAAACTGGGTACCGGTG 
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CTCTGAACGCTGTTCTGAAACAGATGACTAGCATGGG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
CTCTGAACGCTGTTCTGAAACAGATGACTAGCATGGG 
 
TGTTCTGTCTAACGTTATCGGTTACCTGAAAAAACTGG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
TGTTCTGTCTAACGTTATCGGTTACCTGAAAAAACTGG 
 
GTACCGGTGCTCTGAACGCTGTTCTGAAACAGATGACT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GTACCGGTGCTCTGAACGCTGTTCTGAAACAGATGACT 
 
AGTGGGATCC 
 * * * * * * * * * * 
AGNGGGATCC 
 
 
 
